F/M Investments’s Immunovant IMVT Stock Holding History

F/M Investments’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,573	Closed	-$510K	–	398
2024 Q4	$510K	Buy	+20,573	New	+$584K	0.02%	325

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

F/M Investments's IMVT Position: Q1 2025 in Review

F/M Investments sold out of Immunovant (IMVT) in Q1 2025, closing a stake of 20,573 shares — an estimated $510K sold.

F/M Investments first reported a position in IMVT in Q4 2024 and held it in 1 quarter. The position peaked at $510K in Q4 2024. 193 funds tracked by Wall St. Rank hold IMVT as of Q1 2025.

F/M Investments reported no remaining Immunovant position as of Q1 2025 after selling out during the quarter.
F/M Investments sold 20,573 Immunovant shares in Q1 2025, an estimated $510K.
F/M Investments first reported a position in Immunovant in Q4 2024 and held it in 1 quarter.
F/M Investments's Immunovant position peaked at $510K in Q4 2024.
193 funds tracked by Wall St. Rank held Immunovant as of Q1 2025.

Based on F/M Investments's 13F filing for Q1 2025, filed 14 May 2025.